glp-1 drugs pharmaceutical companies partnerships 2025 The Biggest Winner of with a New Drug Breakthrough Perspectives from employers on the

For us, GLP-1s, last year, were number 32, and this year theyre number one [in pharmacy spending]. Human Resources Director, health benefits administrator Before we knew it, we spent half a million dollars and were projected to go up to $1.2 million the following year. Manager of Compensation and Benefits Administration, large retail firm Ill just say our GLP-1 agonist spending year over year was increasing 50% for weight loss

However, the three main SCFAs differ significantly in their potential effect on host physiology

It can also be combined with other compounds that support energy production or fat metabolism

Pistone G, Marino A, Leotta C, et al